1. Therapeutic potential of anti-ErbB3 chimeric antigen receptor natural killer cells against breast cancer
- Author
-
Juheon Lee, Jinhoo Song, Wonbeak Yoo, Hyunji Choi, Dana Jung, Eunjeong Choi, Seo-Gyeong Jo, Eun-Yeung Gong, Young-Hee Jeoung, You-Soo Park, Woo-Chang Son, Hosuk Lee, Hayoung Lee, Jeom Ji Kim, TaeEun Kim, Sooyun Lee, Jang-June Park, Tae-Don Kim, and Seok-Ho Kim
- Subjects
Chimeric antigen receptor (CAR) ,Natural killer (NK) cells ,Breast cancer ,ErbB3 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract ErbB3 is markedly overexpressed in breast cancer cells and is associated with resistance and metastasis. Additionally, ErbB3 expression levels are positively correlated with low densities of tumor-infiltrating lymphocytes, a marker of poor prognosis. Consequently, ErbB3 is a promising therapeutic target for cancer immunotherapy. Here, we report the generation of ErbB3-targeted chimeric antigen receptor (CAR)-modified natural killer (NK) cells by transducing cord blood-derived primary NK cells using vsv-g envelope-pseudotyped lentiviral vectors. Transduced cells displayed stable CAR-expressing activity and increased cytotoxicity against ErbB3-positive breast cancer cell lines. Furthermore, anti-ErbB3 (aErbB3) CAR-NK cells strongly reduced the tumor burden in the SK-BR-3 xenograft mouse model without observable side effects. These findings underscore the potential of aErbB3 CAR-NK cells as targeted immunotherapy for ErbB3-positive breast cancer, suggesting a promising alternative to conventional treatments.
- Published
- 2025
- Full Text
- View/download PDF